Is there a need for another inhalative beta(2)-agonist besides formoterol in patients with asthma?
Formoterol can substitute the rapid- and short-acting beta(2)-agonists as well as the slow- and long-acting salmeterol. Therefore formoterol in a fixed combination with an inhalant steroid reduces the aerosol devices necessary for asthma control to only one, to be used for regular "controller" and, as needed, "rescue therapy". The side effect profile of formoterol is comparable to the short-acting beta(2)-agonists which makes the combination with a topically active glucocorticoid applicable in patients of any asthma severity as long as they are able to perform an inspiratory vital capacity maneuver
Matthys
H
H
Medizinische Klinik, Abteilung Pneumologie Universitätsklinik Freiburg, Hugstetterstr. 55, D-79106 Freiburg, Germany. matthys@med1.ukl.uni-freiburg.de
D000287:Administration, Topical; D000318:Adrenergic beta-Agonists / Q000494:pharmacology / Q000627:therapeutic use*; D000420:Albuterol / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D004983:Ethanolamines / Q000494:pharmacology / Q000627:therapeutic use*; D000068759:Formoterol Fumarate; D005938:Glucocorticoids; D006801:Humans; D000068299:Salmeterol Xinafoate
D000318:Adrenergic beta-Agonists; D000893:Anti-Inflammatory Agents; D004983:Ethanolamines; D005938:Glucocorticoids; D000068299:Salmeterol Xinafoate; D000420:Albuterol; D000068759:Formoterol Fumarate